Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | GOT1 | P17174 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800478 | 0.93 | MAPT (0.40) | KDM4ESMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL4805736 | 0.85 | KDM4E (0.42) | KDM4ESMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL4808609 | 0.85 | KDM4E (0.39) | KDM4ESMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL4806059 | 0.77 | MAPK14 (0.43) | KDR | |
| SCHEMBL4046888 | 0.77 | PTGS2 (0.40) | KDM4ESMN1; SMN2MAPTHTTTDO2 | |
| SCHEMBL3550447 | 0.75 | GOT1 (0.47) | KDM4ESMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL4807527 | 0.75 | KDM4E (0.44) | KDM4EMAPTNPC1RAB9AKMT2A | |
| SCHEMBL4798394 | 0.75 | TDO2 (0.42) | KDM4ESMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL4806361 | 0.72 | KDM4E (0.40) | KDM4ESMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL4801865 | 0.71 | TDO2 (0.35) | KDM4ESMN1; SMN2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699796-A4 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2009-03-04 | — | — | EP | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1699796-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1697370-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-7037910-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050192278-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
| WO-2005063761-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005061509-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BROSTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192278-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | KDM4E 1110/4885SMN1; SMN2 3838/4885LMNA 4396/4885 |
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, CCKBR | KDM4E 1199/4885SMN1; SMN2 3079/4885LMNA 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.